Valuation: Nutriband Inc.

Market Cap 56.72M 48.59M 45.46M 41.62M 78.1M 5.43B 79.14M 537M 209M 2.73B 213M 208M 9.02B P/E 2025
-8.39x
P/E 2026 -1.86x
Enterprise Value 52.4M 44.88M 41.99M 38.44M 72.14M 5.01B 73.1M 496M 193M 2.52B 197M 192M 8.33B EV / Sales 2025
41.1x
EV / Sales 2026 26.5x
Free-Float
43.12%
Yield 2025 *
-
Yield 2026 -
1 day+22.32%
1 week+41.41%
Current month+63.73%
1 month+51.51%
3 months+33.71%
6 months+5.34%
Current year+2.78%
1 week 3.21
Extreme 3.21
4.75
1 month 2.8
Extreme 2.8
4.75
Current year 2.8
Extreme 2.8
4.98
1 year 2.8
Extreme 2.8
8.63
3 years 1.53
Extreme 1.53
11.78
5 years 1.53
Extreme 1.53
12.86
10 years 0.86
Extreme 0.857142
43.54
Manager TitleAgeSince
Chief Executive Officer 35 2015-12-31
Chief Executive Officer 52 -
Director of Finance/CFO 77 2020-09-01
Director TitleAgeSince
Chairman 52 2022-01-20
Director/Board Member 48 2018-06-30
Director/Board Member 38 2018-06-30
Date Insider Type Main position Quantity % Market Cap.
1/31/25 Other

Founder

126,833 1.1420%
1/31/25 Option

Chief Financial Officer

212,837 1.9164%
3/20/24 Free

Chief Financial Officer

162,500 2.0745%
Change 5-day change 1-year change 3-year change Capi.($)
+22.32%+41.41%-26.05%+38.47% 56.72M
+2.19%+4.84%-11.64%+12.29% 202B
+1.14%+2.28%+2.47%+14.39% 119B
+1.06%+1.34%+4.88%+75.73% 60.69B
-1.37%-6.57%+28.86%+58.31% 52.38B
+2.33%+4.69%-2.35%-30.34% 52.3B
+2.35%+2.89%+14.54%-11.79% 34.85B
+5.16%-4.14% - - 30.06B
-0.20%+1.05%+45.52%-10.08% 24.85B
-0.29%-3.87%-6.22%+24.74% 23.84B
Average +3.47%+4.39%+5.56%+19.08% 60.03B
Weighted average by Cap. +1.53%+1.91%+1.96%+17.88%

Financials

2025 2026
Net sales 2.14M 1.83M 1.71M 1.57M 2.95M 205M 2.98M 20.26M 7.9M 103M 8.03M 7.86M 340M 2.04M 1.74M 1.63M 1.49M 2.8M 195M 2.84M 19.29M 7.52M 97.89M 7.65M 7.48M 324M
Net income -10.48M -8.98M -8.4M -7.69M -14.43M -1B -14.62M -99.26M -38.71M -504M -39.36M -38.5M -1.67B -8.23M -7.05M -6.6M -6.04M -11.33M -787M -11.48M -77.93M -30.39M -396M -30.9M -30.23M -1.31B
Net Debt -4.13M -3.53M -3.31M -3.03M -5.68M -395M -5.76M -39.07M -15.23M -198M -15.49M -15.15M -656M -4.33M -3.71M -3.47M -3.18M -5.96M -414M -6.04M -41M -15.99M -208M -16.26M -15.9M -688M
Logo Nutriband Inc.
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Employees
-
Date Price Change Volume
26-08-21 US$4.666 +22.32% 67,093
26-08-20 US$3.815 +7.46% 18,487
26-08-19 US$3.550 +2.90% 7,437
26-08-18 US$3.450 +6.81% 6,373
26-08-17 US$3.230 -2.12% 6,599
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.666USD
Average target price
15.00USD
Spread / Average Target
+221.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRB Stock